12:00 AM
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Stelara ustekinumab: Phase III data

The double-blind Phase III PSUMMIT I trial in 615 patients with active psoriatic arthritis showed that 45 and 90 mg subcutaneous Stelara each met the primary endpoint of improving ACR20 response rates at week 24 vs. placebo (42.4% and 49.5%, respectively, vs. 22.8%, p<0.0001 for both). Low- and high-dose Stelara also met the secondary endpoints of improving ACR50 (24.9% and 27.9%, respectively, vs. 8.7%, p<0.0001 for both) and ACR70 (12.2% and 14.2%, respectively, vs. 2.4%, p<0.0001 for both) response rates at week 24 vs. placebo (p<0.0001 for all). Additionally, a significantly greater proportion of patients receiving low- and high-dose Stelara...

Read the full 478 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >